Delivery Order SPE2DB20D3103-SPE2DB25FQ4Z1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Remifentanil 2 mg vials with a ceiling value of $1,675.46. The contract utilizes a firm fixed price structure and represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This delivery order was competitively awarded with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials under a firm fixed-price contract. The award, issued on August 11, 2025, carries a ceiling value of $7,572.90 with an ultimate completion date of August 12, 2025. This delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Remifentanil is a potent synthetic opioid...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials under a firm fixed-price contract. This award, issued on August 28, 2025, carries a ceiling value of $10,266.97 and is expected to reach ultimate completion on August 29, 2025. The contract is a non-set-aside, competitively awarded delivery order that leverages AmerisourceBergen's broader relationship with DLA to fulfill critical pharmaceutical needs. Performance will be...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, with a ceiling value of $1,422.92. This order was competitively awarded without set-aside designation and carries a firm fixed price contract type with an ultimate completion date of September 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,983.47 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, a potent opioid analgesic commonly used in clinical and surgical settings. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance...
- The Defense Logistics Agency awarded a delivery order valued at $2,925.36 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials. This contract type represents a firm fixed price delivery order with an ultimate completion date of September 18, 2025, and was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,193.89 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Remifentanil is a potent synthetic opioid analgesic commonly used in medical and surgical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,941.00 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials. This firm fixed-price contract, issued on June 6, 2025, with an ultimate completion date of June 9, 2025, represents a competitive award with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Remifentanil is a potent synthetic...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Remifentanil 2 mg vials, with a contract ceiling value of $9,762.12. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,522.64 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials. This is a firm fixed price delivery order, effective through August 25, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Remifentanil is a potent synthetic opioid analgesic commonly used in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ4Z1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 27, 2025, for the supply of Remifentanil 2 mg vials with a ceiling value of $7,142.70. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The performance location is the vendor's corporate office in Conshohocken, Pennsylvania, with completion required by September 29, 2025. Remifentanil is a potent opioid analgesic commonly used in hospital and surgical settings for pain management and anesthesia support within military and federal healthcare systems. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor supporting the Defense Health Agency and broader military healthcare operations. The company's comprehensive federal contract portfolio demonstrates its capability to fulfill specialized pharmaceutical procurement requirements across multiple therapeutic domains, positioning it as a key supplier within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 9/27/25 |